课题基金 / 基金详情

Antigenic Switching by VSG Gene Conversion in T. brucei

Antigenic Switching by VSG Gene Conversion in T. brucei
T. brucei 中 VSG 基因转换的抗原转换
批准号:
6405112
负责人:
TAMARA L HORTON
金额:
$0.33万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
未结题
起止时间:
2001-07-01 至

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by the applicant): Trypanosoma brucei is a eukaryotic parasite that evades mammalian host immune response by antigenic variation: changing its Variant Surface Glycoprotein (vsG) ?coat? by alternatively expressing one among hundreds of highly diverged VSG genes in its genome Most VSG switches occur by the little-studied process of gene conversion. Here, a new strategy is proposed, replacing VSG ORFs with selectable markers, to investigate parameters affecting gene conversion of VSG cassettes. Drug selection will detect recombination of promoter-less markers with the active VSG, allowing isolation and study of rare gene conversion events. The hypothesis that recombination rates differ for internal versus telomeric VSGS will be evaluated by measuring gene conversion from markers placed at each type of site. Creating lines with latent promoters upstream of silent telomeric VSGs will detect otherwise ?silent? switches, which might shuffle and increase the availability of VSGS at ?preferred? chromosornal locations. The reporter constructs can be altered to test the role of conserved sequence motifs of VSG gene conversion cassettes for effects on the rates and order of VSG switching. The influence of chromosomal context and local sequence elements on recombination will be teased apart. A thorough understanding of VSG gene conversion will allow development of more accurate models to explain and predict patterns of antigenic variation. This work is highly relevant to host-pathogen interactions, especially in trypanosomes and malaria parasites.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    王亚伟
  • 依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究